Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients

Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients

Patients with non-small cell lung cancer (NSCLC) have been shown to benefit from the introduction of anti-PD1 treatment. However, not all patients experience tumor regression and durable response. The identification of a string of markers that are direct or indirect indicators of the immune system f...

Full description

Bibliographic Details
Main Authors: Ilaria Grazia Zizzari, Alessandra Di Filippo, Fabio Scirocchi, Francesca Romana Di Pietro, Hassan Rahimi, Alessio Ugolini, Simone Scagnoli, Pamela Vernocchi, Federica Del Chierico, Lorenza Putignani, Aurelia Rughetti, Paolo Marchetti, Marianna Nuti, Andrea Botticelli, Chiara Napoletano
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Journal of Personalized Medicine
Subjects:
non-small cell lung cancer
soluble immune checkpoints
biomarkers
immune checkpoint inhibitors
gut metabolites
immunotherapy
Online Access:https://www.mdpi.com/2075-4426/10/4/208

Internet

https://www.mdpi.com/2075-4426/10/4/208

Similar Items